Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jan;55(1):39-44.
doi: 10.1002/jcph.372. Epub 2014 Aug 22.

Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis

Julie Autmizguine  1 , Michael Cohen-Wolkowiez, Norman Ilowite; RAPPORT Investigators
Collaborators, Affiliations
Randomized Controlled Trial

Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis

Julie Autmizguine et al. J Clin Pharmacol. 2015 Jan.
No abstract available

Keywords: interleukin-1 inhibitor; pediatrics; population pharmacokinetics; systemic juvenile idiopathic arthritis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Final population PK model diagnostic plots, showing observed versus population predictions (A), and individual predictions (B), and weighted residuals versus population predictions (C), and time (D). In panels A and B, the line of identity (solid black line) is included as a reference, and the dotted line represents the linear regression fit. For weighted residuals, a solid line at y = 0 is included as a reference and the dotted line represents the loess line.
Figure 2
Figure 2
Rilonacept clearance (CL/F) vs. age (panel A) and albumin (panel B) Values are individual empirical Bayesian CL/F estimates at first PK sample.
Figure 3
Figure 3. Rilonacept systemic exposure vs. response
Rilonacept response at 12 weeks is defined as a composite of improvement in the American College of Rheumatology Pediatric 30 (ACR Pedi 30) criteria, the absence of fever ≥38.5ºC in the previous 2 weeks, and at least 10% taper in the dose of systemic corticosteroids from baseline in patients receiving corticosteroids. AUC0-inf indicates area under the concentration time curve from 0 to infinity.
See this image and copyright information in PMC

References

    1. Gare BA, Fasth A. Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics. 1992 Dec;90(6):950–958. - PubMed
    1. Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960–1993. Is the epidemiology changing? Arthritis Rheum. 1996 Aug;39(8):1385–1390. - PubMed
    1. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006 Jan;2(1):28–34. - PubMed
    1. Duffy CM. Health outcomes in pediatric rheumatic diseases. Curr Opin Rheumatol. 2004 Mar;16(2):102–108. - PubMed
    1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007 Mar 3;369(9563):767–778. - PubMed

Publication types